NEW YORK, NY / ACCESSWIRE / March 13, 2019 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Corbus Pharmaceuticals Holdings, Inc. ("Corbus"or the "Company") (CRBP). Such investors are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/crbp.
The investigation concerns whether Corbusand certain of its officers and/or directors have violated federal securities laws.
On February 28, 2019, an article entitled "Corbus Has Ties to Suspect Investors And A History of Failed Clinical Trials for Lenabasum" was published on the website Seeking Alpha. The article expressed the belief that lenabasum, Corbus's lead product candidate, "has failed every trial," "has a history of negative clinical data," and "is likely to fail in the company's pivotal trial in Scleroderma and Systemic Sclerosis (SSc) and Phase 2b trial in cystic fibrosis." The article further alleged "ties between Corbus . . . and a group of suspect investors that were involved during the company's IPO." Following the article's publication, Corbus's stock price fell $1.32 per share, or 15.98%, to close at $6.94 per share on February 28, 2019.
If you are aware of any facts relating to this investigation, or purchased Corbusshares,you can assist this investigation by visiting the firm's site: www.bgandg.com/crbp. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | [email protected]
SOURCE: Bronstein, Gewirtz & Grossman, LLC
View source version on accesswire.com:
https://www.accesswire.com/538931/Corbus-Pharmaceuticals-Holdings-Inc-CRBP-Shareholder-Alert-Bronstein-Gewirtz-Grossman-LLC-Announces-Investigation